Citi Maintains Buy on Johnson & Johnson

Citi is out with its report today on Johnson & Johnson JNJ, maintaining Buy. In its report, Citi writes, "We rate the shares of Johnson & Johnson Buy/Low Risk (1L). While each of JNJ's divisions have dealt with a variety of headwinds heading into 2011, the company has enough flexibility below the top line to deliver positive EPS growth." Citi maintains a $73 PT on JNJ. At the time of posting, shares of JNJ were trading pre-market at $65.60, down 0.39% from Monday's close.